|
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline (I) |
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - BTG; Saladax Biomedical |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst); Saladax Biomedical (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst) |
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst) |
|
|
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Cougar Biotechnology; Exelixis; immatics; Medivation; Progenics; PSMA Development Company; Sotio |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Cerulean Pharma; Exelixis |
|
Hussein Abdul-Hassan Tawbi |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |